" class="no-js "lang="en-US"> Gliknik Inc. Raises $11.5 Million in Series C Financing - Medtech Alert
Thursday, June 13, 2024

Gliknik Inc. Raises $11.5 Million in Series C Financing

Gliknik Inc., an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing. First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating. The proceeds are targeted to progress the growing pipeline of product candidates. Gliknik has secured $81 million to date to advance its programs.

“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV. “This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders.”

Funding will help advance clinical and pre-clinical programs, including:

  • A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion. Clinicians are assessing two-year endpoints in the prevention-of-recurrence of high-risk squamous cell oral cavity cancer.
  • Immune modulating compound GL-2045, a recombinant mimetic of pooled human IVIG, which is a potent clinical candidate under active development by Gliknik licensee Pfizer for autoimmune diseases. Gliknik believes that based on potency, purity and anticipated convenience, GL-2045 has the potential to be a disruptive advance for autoimmune diseases that could help address the current critical shortage of IVIG.
  • GL-0719 is a new type of complement modulator, which is designed to control diseases while leaving critical host defense systems intact. GL-0719 is poised to enter a phase 1 trial in 2021.
  • Other compounds in preclinical development

Kyle Rusconi, a founder of FIV, is joining the Board. “During the last several years, Gliknik has created a significant pipeline of important compounds,” said Mr. Rusconi. “This scientific development was done in a capital-efficient manner that preserved shareholder equity.”

“We are humbled by the depth of support from our investor base and welcome the addition of discerning investors with a long-term view,” said Gliknik CEO David Block.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more